

A⁷
cont.

corticosteroid include the proprietary formulations Betnovate RD™ (bethamethasone valerate, ready diluted), Aureocort™ (triamcinolone acetonide and chlortetracycline hydrochloride (an antibiotic)), and Eumovate™ (clobetasone butyrate). A 1% hydrocortisone preparation may also be used.

Page 27, line 29:

A⁸

sorbitan tristearate or Polawax NF™ 2.0%

A⁹

Polawax NF™ 2.0%

Page 30, line 2:

A¹⁰

Miranol™ 2.0%

Page 30, line 3:

A¹¹

Procetyl AWS™

In the Claims

✓
Please cancel Claims 2, 6-8, 14, 16, 18-19, and 24-27.


✓
Please amend Claims 1, 3-5, 9-10, 12-13, 15, 17, 20-23, 28 and 29 as follows.

A¹²
but B!

1. A composition comprising an amphoteric surfactant, an alkoxyolated cetyl alcohol and a polar drug selected from the group consisting of sodium cromoglycate and nedocromil sodium.

A¹³

3. A composition according to Claim 1 wherein the amphoteric surfactant is a balanced amphoteric surfactant.



Sub B2

A¹³

4. A composition according to Claim 1 wherein the alkoxylated cetyl alcohol is polypropoxylated cetyl alcohol.

5. A composition according to Claim 1 wherein the amphoteric surfactant comprises disodium cocoamphodiacetate.

A¹⁴

9. A composition according to Claim 1 wherein the composition further comprises a corticosteroid.

10. A composition according to Claim 1 wherein the composition comprises an aqueous phase and an oil phase.

, does not purify limit

A¹⁵

12. A composition according to Claim 1 wherein the composition is a foam.

13. A composition according to any of the preceding claims consisting substantially of:

sorbitan tristearate or non-ionic emulsifying wax 0.5 to 5% w/v

glycerol monostearate 0.5 to 5% w/v

light liquid paraffin 1 to 20% w/v

white soft paraffin 1 to 10% w/v

iso propyl myristate 0.5 to 5% w/v

polar drug 0.1 to 20% w/v

disodium edetate 0.01 to 1% w/v

amphoteric surfactant 0.1 to 10% w/v

alkoxylated cetyl alcohol 0.1 to 10% w/v

triclosan 0.01 to 1% w/v

benzyl alcohol 0.01 to 1% w/v

A15

cont'd
Subj 3
entity

purified water

to 100% of the emulsion

15. A method for treating a skin disease or condition comprising:

(a) providing a polar drug selected from the group consisting of sodium cromoglycate and nedocromil sodium; and

(b) applying said polar drug to the skin of an individual affected by the disease or condition in or with a formulation comprising alkoxylated cetyl alcohol and an amphoteric surfactant.

17. A composition as in Claim 1 that is useful for

treatment of a skin disease or condition by applying said composition to the skin of an individual affected by the disease or condition.

A17
Subj 5

20. A method as in Claim 15 wherein the disease or condition is one in which skin mast cells and/or delayed hypersensitivity reactions and/or inflammation is thought to be involved.

21. A method as in Claim 15 in which the disease or condition is atopic dermatitis or eczema, contact sensitivity, psoriasis, drug sensitivity reactions, aphous ulcers, Behcet's syndrome, pemphigus, urticaria, urticaria pigmentosa, pyroderma gangrenosum, chronic skin ulcers, ulcers associated with Crohn's disease, burns, insect

A18
Subj 6